# Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

> **NCT06804850** · PHASE2 · WITHDRAWN · sponsor: **West China Hospital**

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Afatinib
- **RADIATION:** Low dose radiotherapy

## Key facts

- **NCT ID:** NCT06804850
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-01-20
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was withdrawn prior to participant enrollment due to administrative and protocol optimization considerations.
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06804850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06804850, "Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06804850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*